Understanding Regulatory Considerations During Feasibility Assessments

Feasibility assessments are a critical step in clinical trial start-up, allowing sponsors and CROs to evaluate whether potential sites can successfully execute a protocol. However, beyond site infrastructure, patient pools, and investigator experience, regulatory compliance is equally vital. Inadequate attention to regulatory requirements during feasibility can lead to delays, rejections, or audit findings. This guide outlines the essential regulatory elements that must be reviewed as part of every feasibility evaluation.

The Role of Regulatory Compliance in Feasibility

Clinical trial regulations set the foundation for ethical conduct, subject protection, and data integrity. Regulatory oversight agencies—such as the USFDA, EMA, and CDSCO—require documented evidence that investigational sites are capable of meeting regulatory standards before approval.

During feasibility, sponsors must verify that a site is not only suitable for operations but also aligns with regional and international guidelines like ICH-GCP. Regulatory gaps at this stage can lead to costly start-up delays or compliance issues post-initiation.

Key Regulatory Checks During Feasibility Assessments

1. Licensing and Accreditation of Site and Investigators

• Principal Investigator (PI) must have valid medical licensure for the country of operation
• Site should be registered with national regulatory authorities (where applicable)
• Verify any historical suspensions, sanctions, or non-compliance records

2. IRB/EC Review Capabilities

• Confirm whether the site has access to a functioning Institutional Review Board or Ethics Committee
• Assess average timelines for initial and continuing review
• Check if the EC complies with national GCP regulations and maintains adequate documentation

3. Informed Consent Process Oversight

• Ensure that informed consent SOPs align with Pharma SOP documentation
• Review the site’s history with vulnerable populations, if applicable
• Determine if translations and local adaptations are supported by EC

4. Regulatory Submissions and Approvals

• Check site familiarity with regulatory submission procedures for CTAs or INDs
• Review documentation timelines from past trials (e.g., CDSCO SUGAM Portal, EMA Clinical Trial Portal)
• Ensure readiness to handle amendments, notifications, and queries during the trial

5. GCP Training and Documentation

• Confirm that all site staff have completed recent GCP training (within 2 years)
• Request training certificates or rosters for documentation
• Evaluate understanding of ICH E6 (R2) and relevant national adaptations

Country-Specific Regulatory Expectations

Each region imposes specific requirements during feasibility. For example:

• India (CDSCO): Sites must be registered with the CDSCO and ECs accredited under NABH or equivalent bodies
• USA (FDA): Requires Form 1572 and Investigator CVs submitted to the IND file
• EU (EMA): Site details must be entered in the CTIS for each trial
• UK (MHRA): Requires pre-approval of site and PI in trial notification

Understanding these differences ensures proper selection and preparedness of sites globally.

Documentation for the Trial Master File (TMF)

As per ICH-GCP and StabilityStudies.in recommendations, feasibility documentation with regulatory components must be maintained in the TMF, including:

• Signed feasibility questionnaires with regulatory declarations
• Copies of licenses, CVs, and GCP training certificates
• EC registration documents
• Feasibility decision-making justifications

Creating a Regulatory Feasibility Checklist

Sponsors should include a dedicated regulatory section in their feasibility checklist covering:

• PI licensing status and experience
• EC operational capability and accreditation
• Historical compliance data (e.g., audit findings, inspection outcomes)
• Submission readiness and GCP compliance

This can be developed into a site scorecard and integrated with the overall site qualification process.

Common Pitfalls and How to Avoid Them

• Assuming EC availability: Always confirm the EC is currently functioning and accepting reviews
• Overlooking licensing renewals: PI or staff may have expired registrations
• Inconsistent GCP records: Ensure centralized verification of training validity
• Lack of audit documentation: Request recent inspection reports, especially if conducted by agencies like TGA or ANVISA

Integrating with Site Feasibility SOPs

Your feasibility SOP should clearly assign responsibilities to regulatory affairs or clinical operations teams for verifying these elements. Regulatory feasibility should be completed before final site approval and revisited during site initiation.

Conclusion

Regulatory considerations are a foundational component of feasibility assessments. They ensure that sites are compliant, inspection-ready, and capable of meeting trial expectations. By embedding regulatory checks early in the feasibility process, sponsors can avoid costly delays and ensure seamless clinical trial execution with full compliance to global standards.